Viatris IncViatris Inc
Viatris Inc

Viatris Inc

VTRS
Health Care·Pharmaceuticals

Viatris, Inc. is a global healthcare company, which engages in the provision of healthcare and pharmaceutical products. It provides medicines and treatments in various therapeutic areas such as cardiovascular, oncology, dermatology, eye care, gastroenterology, immunology, and women's healthcare. The firm operates through the following segments: Developed Markets, Greater China, JANZ, and Emerging Markets. The Developed Markets segment consists of operations primarily in North America and Europe. The Greater China segment includes operations in mainland China, Taiwan, and Hong Kong. The JANZ segment covers operations in Japan, Australia, and New Zealand. The Emerging Markets segment encompasses operations in developing markets and emerging economies including in Asia, the Middle East, South and Central America, Africa, and Eastern Europe. The company was founded on February 14, 2019 and is headquartered in Canonsburg, PA.

Pennsylvania; U.S.A
Market cap
No dataNo data
Revenue
$14.3B−3.0% YoY
Net income
$-3.5B−454.2% YoY
Free cash flow
$1.9B−2.0% YoY

Market

Listed stock
VTRSPriceNasdaq
Loading…Loading…1Y

Financial performance

Revenue
$14.3B−3.0% YoY
Operating income
$-2.7B−26467.3% YoY
Net income
$-3.5B−454.2% YoY
Free cash flow
$1.9B−2.0% YoY

Revenue, profit & cash trend

Revenue
Operating income
Net income
Free cash flow
Reference
Revenue: 2021 $17.9B, 2022 $16.3B, 2023 $15.4B, 2024 $14.7B, 2025 $14.3B. Operating income: 2021 $-34M, 2022 $1.6B, 2023 $766.2M, 2024 $10.1M, 2025 $-2.7B. Net income: 2021 $-1.3B, 2022 $2.1B, 2023 $54.7M, 2024 $-634.2M, 2025 $-3.5B. Free cash flow: 2021 $2.6B, 2022 $2.5B, 2023 $2.4B, 2024 $2B, 2025 $1.9B. Reference line: Reference at $0.

Growth & profitability

Revenue growth
-3.0%+148 bps YoY
Gross margin
No dataNo data
Operating margin
No dataNo data
FCF margin
No dataNo data

Earnings power over time

Operating income
Net income
Free cash flow
Operating income: 2021-12-31 $-34M, 2022-12-31 $1.6B, 2023-12-31 $766.2M, 2024-12-31 $10.1M, 2025-12-31 $-2.7B. Net income: 2021-12-31 $-1.3B, 2022-12-31 $2.1B, 2023-12-31 $54.7M, 2024-12-31 $-634.2M, 2025-12-31 $-3.5B. Free cash flow: 2021-12-31 $2.6B, 2022-12-31 $2.5B, 2023-12-31 $2.4B, 2024-12-31 $2B, 2025-12-31 $1.9B

Growth heatmap

2022202320242025CAGR
Revenue
-9.1%
-5.1%
-4.5%
-3.0%
-5.4%
Gross profit
+16.5%
-0.9%
-12.7%
-10.8%
-2.6%
Operating income
+4849.7%
-52.6%
-98.7%
-26467.3%
No data
Free cash flow
-0.5%
-4.9%
-18.4%
-2.0%
-6.7%

Earnings quality

Operating cash flow
$2.3B+0.6% YoY
Net income
$-3.5B−454.2% YoY
Free cash flow
$1.9B−2.0% YoY
Diluted EPS
No dataNo data

Cash conversion quality

Operating cash flow
Free cash flow
Net income = 100%
Operating cash flow: 2025-12-31 -66%, 2024-12-31 -363%, 2023-12-31 5118%, 2022-12-31 142%, 2021-12-31 -238%. Free cash flow: 2025-12-31 -55%, 2024-12-31 -312%, 2023-12-31 4429%, 2022-12-31 123%, 2021-12-31 -202%. Reference line: Net income = 100% at 100%.

Per-share economics

Diluted EPS
Latest
No data
FCF / share
Latest
No data
Diluted shares
Latest
No data

Financial flexibility

Cash & equivalents
No dataNo data
Total debt
No dataNo data
Net debt
No dataNo data
Current ratio
No dataNo data

Cash Coverage of Debt

Cash / Total debt
No data

Returns

Return on equity
No dataNo data
Return on assets
No dataNo data
Return on invested capital
No dataNo data
Asset turnover
No dataNo data

Return on capital

No data

Valuation

Price to earnings
No dataNo data
Price to sales
No dataNo data
EV / EBITDA
No dataNo data
Free cash flow yield
No dataNo data

Valuation vs its own 5Y history

Metric
Own five-year range
Current
Own 5Y median
Position in own range
Price to earnings
No data
No data
No data
No data
Price to sales
No data
No data
No data
No data
EV / EBITDA
No data
No data
No data
No data
Free cash flow yield
No data
No data
No data
No data